Becton Dickinson Announces €600 Million Senior Notes Offering

Becton Dickinson ( (BDX) ) has issued an announcement.

On May 11, 2026, Becton, Dickinson and Company and its Luxembourg-based financing subsidiary entered into an underwriting agreement for a €600 million offering of 3.855% notes due 2033, which will be fully and unconditionally guaranteed on a senior unsecured basis by BD. The company plans to use the proceeds, together with cash on hand, to repay its outstanding 1.208% euro notes due June 4, 2026, including accrued interest, fees and expenses, with the offering expected to close around May 20, 2026, thereby extending its debt maturity profile and potentially strengthening its balance sheet and financing flexibility.

The most recent analyst rating on (BDX) stock is a Buy with a $204.00 price target. To see the full list of analyst forecasts on Becton Dickinson stock, see the BDX Stock Forecast page.

Spark’s Take on BDX Stock

According to Spark, TipRanks’ AI Analyst, BDX is a Neutral.

BDX earns a mid-range score primarily due to strong free cash flow generation and improving leverage, reinforced by raised adjusted EPS guidance and substantial capital returns. The score is held back by recent revenue/profitability softness and a technically weak chart (below major moving averages with negative MACD), while valuation support comes mainly from the dividend given the negative P/E.

To see Spark’s full report on BDX stock, click here.

More about Becton Dickinson

Becton, Dickinson and Company is a global medical technology firm that develops and manufactures medical devices, instrument systems and reagents for healthcare providers and laboratories. The company focuses on improving medication management, diagnostic accuracy and patient care through a broad portfolio used across hospitals, clinics and research settings.

Average Trading Volume: 2,789,497

Technical Sentiment Signal: Strong Sell

Current Market Cap: $41.17B

For an in-depth examination of BDX stock, go to TipRanks’ Overview page.